TfR1 Humanized Antibodies and Cancer Treatment Methods

ChangeBridge: Patent Grants - Peptides (C07K)

Published April 7th, 2026

Detected April 7th, 2026

Summary

The USPTO issued Patent US12595310B2 to The Regents of the University of California covering transferrin receptor 1 (TfR1)-binding proteins, including humanized antibodies and methods for treating cancer. The patent, granted on April 7, 2026, includes 20 claims and was filed on November 6, 2020 under Application No. 17775167. The invention relates to humanized TfR1-binding proteins with amino acid substitutions, combination treatments with additional therapeutics, and methods for cancer therapy.

View original document View source feed page

What changed

USPTO granted Patent US12595310B2 for compositions and methods involving transferrin receptor 1 (TfR1)-binding proteins, specifically humanized antibodies designed for cancer treatment. The patent covers antibodies with amino acid substitutions such as backmutations, methods for treating cancer using humanized TfR1-binding proteins, and combination therapies with additional therapeutics. The patent is classified under C07K 16/2881 (humanized antibodies) with therapeutic application A61P 35/00 (antineoplastic agents).

Pharmaceutical and biotechnology companies developing antibody-based cancer therapeutics must consider this patent when designing research programs targeting TfR1. Competitors in the antibody therapeutics space should conduct freedom-to-operate analyses to avoid infringing the 20 granted claims. Research institutions and trial sponsors conducting TfR1-related oncology research may need to seek licensing from the University of California to avoid potential IP disputes.

What to do next

Review patent claims for potential infringement in oncology drug development programs
Monitor competitive landscape for TfR1-targeting antibody therapeutics
Assess licensing opportunities with University of California technology transfer office

Source document (simplified)

← USPTO Patent Grants

Compositions and methods for transferrin receptor 1 targeting

Grant US12595310B2 Kind: B2 Apr 07, 2026

Assignee

The Regents of the University of California

Inventors

Manuel L. Penichet, Tracy R. Wells, Pierre V. Candelaria, Juan C. Almagro

Abstract

Aspects of the disclosure relate to transferrin receptor 1 (TfR1)-binding proteins. In some cases, humanized TfR1-binding proteins are described. Embodiments include methods for treating one or more conditions, for example cancer, using a humanized TfR1-binding protein. In some embodiments, the disclosed methods and compositions involve one or more antibodies that are capable of binding TfR1. Certain aspects relate to humanized antibodies and antibody-like molecules comprising one or more amino acid substitutions (e.g., backmutations). Additional aspects relate to combination treatments with TfR1-binding proteins and one or more additional therapeutics.